Issue 2/2014
Content (11 Articles)
Protein recycling pathways in neurodegenerative diseases
Faisal Fecto, Y Taylan Esengul, Teepu Siddique
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Jeremy H Toyn, Michael K Ahlijanian
Neuroimaging characteristics of dementia with Lewy bodies
Elijah Mak, Li Su, Guy B Williams, John T O’Brien
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
Lars Lannfelt, Christer Möller, Hans Basun, Gunilla Osswald, Dag Sehlin, Andrew Satlin, Veronika Logovinsky, Pär Gellerfors
Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery
Lauren G Friedman, Katherine Price, Rachel F Lane, Aaron J Carman, Penny A Dacks, Diana W Shineman, Howard M Fillit
Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach
Hugo Vanderstichele, Thomas Kodadek
Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels
Keith A Wesnes, Peter Annas, Hans Basun, Chris Edgar, Kaj Blennow
Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study
Thomas Leyhe, Niels Andreasen, Monica Simeoni, Arno Reich, Christine AF von Arnim, Xin Tong, Astrid Yeo, Shahid Khan, Amy Loercher, Michelle Chalker, Charles Hottenstein, Henrik Zetterberg, Jan Hilpert, Prafull Mistry
Platelet-activating factor antagonists enhance intracellular degradation of amyloid-β42 in neurons via regulation of cholesterol ester hydrolases
Charlotte Simmons, Victoria Ingham, Alun Williams, Clive Bate
TMEM106B expression is reduced in Alzheimer’s disease brains
Jun-ichi Satoh, Yoshihiro Kino, Natsuki Kawana, Yoji Yamamoto, Tsuyoshi Ishida, Yuko Saito, Kunimasa Arima